OECD principles of Good laboratory practice. this ppt include the basic and necessary information required for OECD GLP guideline . Content is taken from official site
Regulatory guidelines for conducting toxicity studies by ichAnimatedWorld
ICH is the “International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use”
ICH is a joint initiative involving both regulators and research based industry representatives of the EU, Japan and the US in
scientific and technical discussions of the testing procedures required
to assess and ensure the safety, quality and efficacy of medicines
Dermal Irritation and Dermal Toxicity Studies Dinesh Gangoda
Dermal irritation and Corrosion test guidelines 204.
Dermal irritation is the production of reversible damage of the skin following the application of a test chemical for up to 4 hours.
Corrosive reactions are typified by ulcers, bleeding, bloody scabs, and, by the end of observation at 14 days, by discolouration due to blanching of the skin, complete areas of alopecia, and scars. Histopathology should be considered to evaluate questionable lesions. [1]
Dermal corrosion is the production of irreversible damage of the skin; namely, visible necrosis through the epidermis and into the dermis, following the application of a test chemical for up to four hours.[2]
REFERENCES
OECD/OCDE, Test No. 404: ‘‘Acute Dermal Irritation/Corrosion’’, 28 July 2015 OECD Publishing, peris, Page no, 1- 8.
Robert A., Turner., Screening Methods in Pharmacology; 1st edition; Academic press an imprint of Elsevier, pp, 279- 281.
OECD Guideline for testing of chemicals (1981). ‘‘Repeated Dose Dermal Toxicity’’, 21/28- day Study.
OECD principles of Good laboratory practice. this ppt include the basic and necessary information required for OECD GLP guideline . Content is taken from official site
Regulatory guidelines for conducting toxicity studies by ichAnimatedWorld
ICH is the “International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use”
ICH is a joint initiative involving both regulators and research based industry representatives of the EU, Japan and the US in
scientific and technical discussions of the testing procedures required
to assess and ensure the safety, quality and efficacy of medicines
Dermal Irritation and Dermal Toxicity Studies Dinesh Gangoda
Dermal irritation and Corrosion test guidelines 204.
Dermal irritation is the production of reversible damage of the skin following the application of a test chemical for up to 4 hours.
Corrosive reactions are typified by ulcers, bleeding, bloody scabs, and, by the end of observation at 14 days, by discolouration due to blanching of the skin, complete areas of alopecia, and scars. Histopathology should be considered to evaluate questionable lesions. [1]
Dermal corrosion is the production of irreversible damage of the skin; namely, visible necrosis through the epidermis and into the dermis, following the application of a test chemical for up to four hours.[2]
REFERENCES
OECD/OCDE, Test No. 404: ‘‘Acute Dermal Irritation/Corrosion’’, 28 July 2015 OECD Publishing, peris, Page no, 1- 8.
Robert A., Turner., Screening Methods in Pharmacology; 1st edition; Academic press an imprint of Elsevier, pp, 279- 281.
OECD Guideline for testing of chemicals (1981). ‘‘Repeated Dose Dermal Toxicity’’, 21/28- day Study.
This presentation enlists all the studies which are required before submission of IND. It include IND introduction , time period of study ,flowchart showing preclinical studies...
Assignment on Regulatory Prespectives of Clinical TrialsDeepak Kumar
Assignment on Origin and Principles of International Conference on Harmonization - Good Clinical Practice, (ICH-GCP) guidelines Ethical Committee- Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant-Schedule Y, ICMR
A brief introduction about Pharmacology of free radicals, generation of free radicals, Antioxidants, Free radicals causing disorders such as cancer diabetes, neuro degenerative disorders such as Parkisonism's Disease
This presentation enlists all the studies which are required before submission of IND. It include IND introduction , time period of study ,flowchart showing preclinical studies...
Assignment on Regulatory Prespectives of Clinical TrialsDeepak Kumar
Assignment on Origin and Principles of International Conference on Harmonization - Good Clinical Practice, (ICH-GCP) guidelines Ethical Committee- Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant-Schedule Y, ICMR
A brief introduction about Pharmacology of free radicals, generation of free radicals, Antioxidants, Free radicals causing disorders such as cancer diabetes, neuro degenerative disorders such as Parkisonism's Disease
Curcumin is a lipophilic polyphenol and thus is insoluble in water, but is readily soluble in organic solvents such as dimethylsulfoxide, acetone and ethanol [20,22]. The antioxidant activity of the curcuminoids comes by virtue of their chemical structure. The curcuminoids consist of two methoxylated phenols connected by two α, B unsaturated carbonyl groups that exist in a stable enol form [23]. Curcumin has been shown to inhibit lipid peroxidation using linoleate, a polyunsaturated fatty acid that is able to be oxidized and form a fatty acid radical. It has been demonstrated that curcumin acts as a chain-breaking antioxidant at the 3' position, resulting in an intramolecular Diels-Alder reaction and neutralization of the lipid radicals [24]. In addition to inhibiting lipid peroxidation, curcumin demonstrates free radical-scavenging activity. It has been shown to scavenge various reactive oxygen species produced by macrophages (including superoxide anions, hydrogen peroxide and nitrite radicals) both in vitro as well as in vivo using rat peritoneal macrophages as a model [25,26]. Inducible nitric oxide synthase (iNOS) is an enzyme found in macrophages that generates large amounts of NO to provide the 'oxidative burst' necessary for defense against pathogens. iNOS is induced in response to an oxidative environment, and the NO generated can react with superoxide radicals to form peroxynitrite, which is highly toxic to cells. It has been shown that curcumin downregulates the iNOS activity in macrophages, thus reducing the amount of reactive oxygen species (ROS) generated in response to oxidative stress [27,28]. Additional studies in microglial cells (brain macrophage analogs) demonstrated reduced NO generation and protection of neural cells from oxidative stress following curcumin treatment, thus the spice and may be useful in reducing the neuroinflammation associated with degenerative conditions such as Alzheimer's disease [29-31].
This presentation is for the pharmacy, nursing and medical students. this presentation is about brief discussion on good laboratory practice (GLP) for the exam point of view.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
OECD principles of GLP
1. THE OECD PRINCIPLES OF GLP
Presented by : Megha G. Bhise
Department of regulatory affairs
Parul institute of pharmacy
1
2. CONTENT
1. Introduction
2. Facilities
3. Test Systems
4. Test and Reference Items
5. Standard Operating Procedures
6. Performance of the Study
7. Reporting of Study Results
8. Storage and Retention of Records and Materials. 2
3. INTRODUCTION
GLP is quality system concerned with the organizational process and
conditions under which non-clinical health and environmental safety
studies are planned , performed, recorded archived and reported.
The purpose of these Principles of Good Laboratory Practice is to promote
the development of quality test data.
The application of these Principles should help to avoid the creation of
technical barriers to trade, and further improve the protection of human
health and the environment
3
4. 1. FACILITIES
1.1 GENERAL FACILITIES
suitable size, construction and location to meet the requirements of the study and
to minimise disturbance that would interfere with the validity of the study.
adequate degree of separation of the different activities to assure the proper
conduct of each study.
4
5. CONTD….
1.2 TEST SYSTEM FACILITIES
• The testing facility should provide separation of activities to prevent
interference and other disturbances which may compromise the study.
• a sufficient number of rooms or areas to assure the isolation of test systems
and the isolation of individual projects, involving substances or organisms
known to be or suspected of being biohazardous.
• Suitable rooms or areas should be available for the diagnosis, treatment
and control of diseases. 5
6. CONTD….
1.3 FACILITIES FOR HANDLING TEST AND
REFERENCE ITEMS
separate rooms or areas for receipt and storage of the test and reference items, and
mixing of the test items with a vehicle.
Storage rooms or areas for the test items should be separate from rooms or areas
containing the test systems.
Storage areas should be adequate to preserve identity, concentration, purity, and
stability, and ensure safe storage for hazardous substances.
6
7. CONTD….
1.4 ARCHIVE FACILITIES
Archive facilities should be provided for
the secure storage and retrieval of study
plans, raw data, final reports, samples of
test items and specimens.
Archive design and archive conditions
should protect contents from untimely
deterioration.
7
8. CONTD….
1.5 WASTE DISPOSAL
Handling and disposal of wastes should be
carried out in such a way as not to jeopardise the
integrity of studies.
This includes provision for appropriate
collection, storage and disposal facilities, and
decontamination and transportation procedures.
8
9. 2. APPARATUS, MATERIAL, AND REAGENTS
Apparatus should be suitably located and of appropriate
design and adequate capacity
Periodically inspected, cleaned, maintained, and
calibrated according to Standard Operating Procedures.
Apparatus and materials used in a study should not
interfere adversely with the test systems.
9
10. CONTD….
Chemicals, reagents, and solutions should be labelled to indicate identity
(with concentration if appropriate), expiry date and specific storage
instructions.
Information concerning source, preparation date and stability should be
available.
The expiry date may be extended on the basis of documented evaluation
or analysis.
10
11. 3. TEST SYSTEMS
Any biological ,chemical or physical system or a combination there of used
in study.
• Physical /Chemical
Location
Design
Capacity
11
12. CONTD….
• BIOLOGICAL
Proper conditions should be established and maintained for the storage, housing,
Handling and care of biological test systems
Newly received animal and plant test systems should be isolated until their health status
has been evaluated
Test systems should be free of any disease or condition that might interfere with the
purpose or conduct of the study
12
13. CONTD….
Records of source, date of arrival, and arrival condition of test systems
should be maintained.
acclimatized to the test environment for an adequate period before the first
administration/application of the test or reference item.
Test systems used in field studies should be located so as to avoid
interference in the study from spray drift and from past usage of pesticides.
13
14. 4. TEST AND REFERENCE ITEMS
4.1. RECEIPT, HANDLING, SAMPLING AND
STORAGE
Records including test item and reference item characterisation, date of receipt,
expiry date, quantities received and used in studies should be maintained.
Handling, sampling, and storage procedures should be identified
Storage container(s) should carry identification information, expiry date, and
specific storage instructions.
14
15. 4.2 CHARACTERISATION
Each test and reference item should be appropriately identified (e.g., code,
Chemical Abstracts Service Registry Number [CAS number], name,
biological parameters).
For each study, the identity, including batch number, purity, composition,
concentrations, or other characteristics to appropriately define each batch of
the test or reference items should be known.
CONTD….
15
16. The stability of test and reference items under storage and test conditions
should be known for all studies.
A sample for analytical purposes from each batch of test item should be
retained for all studies except short-term studies.
CONTD….
16
17. 5. STANDARD OPERATING PROCEDURES
A test facility should have the written SOPs approved by test facility
management to ensure the quality and integrity of the data generated by
that test facility.
Deviations from Standard Operating Procedures related to the study
should be documented and should be acknowledged by the Study Director
and the Principal Investigator(s), as applicable.
17
18. Standard Operating Procedures should be available for, but not be limited
to, the following categories of test facility activities.
1. Test and Reference Items
• Receipt, identification, labelling, handling, sampling and storage.
2. Apparatus, Materials and Reagents
a) Apparatus
• Use, maintenance, cleaning and calibration.
CONTD….
18
19. b) Computerised Systems
• Validation, operation, maintenance, security, change control and back-up.
c) Materials, Reagents and Solutions
• Preparation and labelling
CONTD….
19
20. CONTD….
3. Record Keeping, Reporting, Storage, and Retrieval
Coding of studies, data collection, preparation of reports, indexing systems,
handling of data, including the use of computerised systems.
4. Test System
Room preparation and environmental room conditions for the test system.
Procedures for receipt, transfer, proper placement, characterisation, identification
and care of the test system.
20
22. 5. PERFORMANCE OF THE STUDY
1) STUDY PLAN
approved by the test facility management and the sponsor, if required by
national regulation or legislation in the country where the study is being
performed.
For short-term studies, a general study plan accompanied by a study
specific supplement may be used.
22
23. 2. CONTENT OF THE STUDY PLAN
i. Identification of the Study, the Test Item and Reference Item
ii. Information Concerning the Sponsor and the Test Facility
iii. Dates
iv. Test Methods
v. Records
CONTD….
23
24. CONTD….
3. CONDUCT OF THE STUDY
A unique identification should be given to each study. All items
concerning this study should carry this identification.
conducted in accordance with the study plan
Specimens from the study should be identified to confirm their origin.
24
25. 6. REPORTING OF STUDY RESULTS
A final report should be prepared for each study.
Reports of Principal Investigators or scientists involved in the study
should be signed and dated by them.
The final report should be signed and dated by the SD to indicate
acceptance of responsibility for the validity of the data.
Corrections and additions to a final report should be in the form of
amendments
25
26. CONTD….
CONTENT OF THE FINAL REPORT
The final report should include
1) Identification of the Study, the Test Item and Reference Item
2) Information Concerning the Sponsor and the Test Facility
3) Dates
4) Statement
26
28. 7. STORAGE AND RETENTION OF
RECORDS AND MATERIALS
The SD will be responsible for ensuring that all data related to the study
is captured and included in records that are safely stored. These records
and documents such as the protocol, the final report, and standard
operating procedures will then be archived at the end of the study.
28
29. CONTD…
The following should be retained in the archives specifie by the appropriate
authorities.
a) The study plan, raw data, samples of test and reference items, specimens,
and the final report of each study;
b) Records of qualifications, training, experience and job descriptions of
personnel;
c) Records and reports of the maintenance and calibration of apparatus;
d) Validation documentation for computerised systems; 29
30. CONCLUSION
GLP is FDA regulations which is accepted and approved as international
standards by OECD to avoid fraud activities of the testing laboratories for
pharmaceuticals to save human and environmental health.
It gives better image of company as quality producer in global market.
Also it establish good relationship among the countries.
30
31. REFERENCES
1. Brunetti MM. Critical aspects in the application of the principles of good
laboratory practice (GLP). ANNALI-ISTITUTO SUPERIORE DI
SANITA. 2002 Jan 1;38(1):41-6.
2. OECD. OECD series on principles of good laboratory practice and
compliance monitoring. OECD; 2007.
3. https://safetyculture.com/topics/good-laboratory-practice-glp/
4. https://dst.gov.in/sites/default/files/No3.pdf
5. https://www.oecd-ilibrary.org/environment/oecd-series-on-principles-of-
good-laboratory-practice-and-compliance-monitoring_2077785x
31